Orforglipron Explained

Drug Name:	Orforglipron
Width:	280
C:	48
H:	48
F:	2
N:	10
O:	5
Iupac Name:	3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one
Cas Number:	2212020-52-3
Chemspiderid:	71117507
Pubchem:	137319706
Unii:	7ZW40D021M
Chembl:	4446782
Smiles:	C[C@H]1C[C@]1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)[C@H]5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7[C@@H]6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C
Stdinchi:	1S/C48H48F2N10O5/c1-25-18-32(19-26(2)40(25)49)60-42(58-16-15-57(46(58)63)37-11-10-36-33(41(37)50)24-51-55(36)7)39-28(4)56(14-12-34(39)53-60)43(61)38-21-31-20-29(30-13-17-64-47(5,6)23-30)8-9-35(31)59(38)48(22-27(48)3)44-52-45(62)65-54-44/h8-11,15-16,18-21,24,27-28,30H,12-14,17,22-23H2,1-7H3,(H,52,54,62)/t27-,28-,30-,48-/m0/s1
Stdinchikey:	USUWIEBBBWHKNI-KHIFEHGGSA-N

Orforglipron (LY-3502970) is an oral, non-peptide, small molecule glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company.^{[1] [2]} It is easier to produce than current peptide GLP-1 agonists and is expected to be cheaper.^[3]

See also

• Danuglipron
• Lotiglipron

Notes and References

1. Pratt E, Ma X, Liu R, Robins D, Coskun T, Sloop KW, Haupt A, Benson C . 6 . Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes . Diabetes, Obesity & Metabolism . June 2023 . 25 . 9 . 2642–2649 . 10.1111/dom.15150 . 37264711 . 259022851 . free .
2. Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M . 6 . Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity . The New England Journal of Medicine . June 2023 . 389 . 10 . 877–888 . 10.1056/NEJMoa2302392 . 37351564 .
3. Sidik . Saima . Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective . Nature . 2023 . 619 . 7968 . 19 . 10.1038/d41586-023-02092-9 . 37369789 . 2023Natur.619...19S . en.